Interestingly, these mutations seem to correlate with specific patterns of PD-L1 expression, although it remains to be investigated if the responsiveness of TC to Pembrolizumab is related to the genomic characteristics of the tumor or to the levels of PD-L1 [80]. Here, CD274 is linked to neoplasm.